t its most basic, science is about models. Natural phenomena that were perplexing to ancient humans have been systematically illuminated as sci entific models have revealed the mathemat ical order underlying the natural world. But what happens when the models themselves become complex enough that they too must be interpreted to be understood?
In 2012, Jonathan Karr, Markus Covert and colleagues at the University of Cali fornia, San Diego (USA) produced a bold new biological model that attempts to sim ulate an entire cell: iMg [1] . iMg merges 28 submodules of processes within Mycobacterium genitalium, one of the sim plest organisms known to man. As a systems biology bigdata model, iMg is unique in its scope and is an undeniable paragon of good craft. Because it is probable that this landmark paper will soon be followed by other whole cell models, we feel it is timely to examine this important endeavour, its challenges and potential pitfalls.
Building a model requires making many decisions, such as which processes to glaze over and which to reconstruct in detail, how many and what kinds of connections to forge between the model's constituents, and how to determine values for the model's para meters. The standard practice has been to tune a model's parameters and its structure to a best fit with the available data. But this approach breaks down when building a large whole cell model because the number of decisions inflates with the model's size, and the amount of data required for these deci sions to be unequivocal becomes huge. This problem is fundamental, not merely techni cal, and is rooted in the principle of frugality that underlies all science: Occam's razor.
The problem posed by Occam's razor is that there are vastly more potential large models that can successfully predict and explain any given body of data than there are small ones. As we can tweak increas ingly complex models in an increasing number of ways, we can produce many large models that fit the data perfectly and yet do not reflect the cellular reality. Even if a model fits all the data well, the chance of it happening to be the 'correct' model-in other words the one that reflects correctly the underlying cellular architecture and rel evant enzymatic parameters-is inversely related to its complexity. A sophisticated large model such as iMg, which has been fit ted to many available datasets, will certainly recapture many behaviours of the real sys tem. But it could also recapture many other potentially wrong ones.
How do we test a model's correctness in the sense just mentioned? The intuitive way is to make and test predictions about previously uncharted phenomena. But vali dating a large biological model is an inher ently different challenge than the common practice of "predict, test and validate" cus tomary with smaller ones. Validation using phenotypic 'emerging' predictions would require such large amounts of data that it would be highly inefficient and costly at this scale, especially as many of these predic tions will turn out to be false leads, with neg ative results yielding little insight. Rather, the correctness of a wholecell model is perhaps best validated by using a complementary paradigm: direct testing of the basic deci sions that went into the model's construc tion. For example, enzymatic rate constants that were fitted in order to make the model behave properly could be experimentally scrutinized for later versions. Performing extensive sensitivity analyses and incorpo rating known confidence levels of model ling decisions, or harnessing more advanced methods such as 'active learning' should all be used in conjunction to determine which parameters to focus on in the future. The process of validating a large model should thus be viewed as an ongoing mission that aims to produce more refined and accurate drafts by improving lowconfidence areas or gaps in the model's construction.
Step by step, this para digm should increase a model's reliability and ability to make valid new predictions.
An open discussion of the potential pit falls and benefits of building complex bio logical models could not be timelier, as both the EU and the US have just committed more than a combined 1.4 billion dollars to explicitly model the human brain. Massive data collection and big data analysis are the new norm in most fields, and big mod els are following closely behind. Their cost, usefulness and application remain open for discussion, but we certainly laud the spirit of the effort. For what is certain is this: only by building these models will we know what usefulness we can attribute to them. Paraphrasing Paul Cezzane, these efforts might be indeed justified and worthy, so long as one is "more or less master of his model".
